HF
FATE icon

HRT Financial’s Fate Therapeutics FATE Stock Holding History

HRT Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Buy
123,488
+113,090
+1,088% +$209K ﹤0.01% 2990
2026
Q1 		$12K Sell
10,398
-38,146
-79% -$46.4K ﹤0.01% 3619
2025
Q4 		$47K Sell
48,544
-12,333
-20% -$14.8K ﹤0.01% 2881
2025
Q3 		$76K Buy
+60,877
New +$65.6K ﹤0.01% 2554
2025
Q1 		– Sell
-29,173
Closed -$48K – 2757
2024
Q4 		$48K Sell
29,173
-179,971
-86% -$453K ﹤0.01% 2114
2024
Q3 		$732K Buy
209,144
+150,118
+254% +$584K ﹤0.01% 1406
2024
Q2 		$193K Buy
+59,026
New +$258K ﹤0.01% 1672
2024
Q1 		– Sell
-395,753
Closed -$1.48M – 2539
2023
Q4 		$1.48M Sell
395,753
-277,537
-41% -$655K 0.01% 797
2023
Q3 		$1.43M Buy
673,290
+411,679
+157% +$1.36M 0.01% 789
2023
Q2 		$1.25M Buy
+261,611
New +$1.44M 0.01% 816
2023
Q1 		– Sell
-37,915
Closed -$382K – 2691
2022
Q4 		$382K Sell
37,915
-68,210
-64% -$1.28M 0.01% 1594
2022
Q3 		$2.38M Buy
+106,125
New +$3.07M 0.03% 543
2021
Q4 		– Sell
-56,876
Closed -$3.37M – 3442
2021
Q3 		$3.37M Sell
56,876
-57,067
-50% -$4.48M 0.02% 467
2021
Q2 		$9.89M Buy
+113,943
New +$9.18M 0.09% 186
2021
Q1 		– Sell
-16,241
Closed -$1.48M – 2822
2020
Q4 		$1.48M Buy
+16,241
New +$1.01M 0.03% 438
2019
Q4 		– Sell
-28,603
Closed -$444K – 1300
2019
Q3 		$444K Buy
+28,603
New +$548K 0.02% 737
2018
Q4 		– Sell
-35,845
Closed -$583K – 637
2018
Q3 		$583K Buy
+35,845
New +$424K 0.09% 158

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRT Financial's FATE Position: Q2 2026 in Review

HRT Financial increased its Fate Therapeutics (FATE) stake by 1,088% in Q2 2026, buying an estimated $209K and bringing the position to 123,488 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #2990.

HRT Financial first reported a position in FATE in Q3 2018 and has held it in 17 quarters since. The position peaked at $9.89M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • HRT Financial held 123,488 shares of Fate Therapeutics worth $333K as of Q2 2026.
  • HRT Financial bought 113,090 Fate Therapeutics shares in Q2 2026, an estimated $209K.
  • Fate Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #2990 holding.
  • HRT Financial first reported a position in Fate Therapeutics in Q3 2018 and has held it in 17 quarters since.
  • HRT Financial's Fate Therapeutics position peaked at $9.89M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.